Clinical Corner
Trials + Updates
Newly renovated Pediatric Infusion Center and Specialties Clinic officially open
On Friday, Dec. 21, 2018, the newly renovated Pediatric Infusion Center and Specialties Clinic began welcoming patients on the fourth floor of UF Health Shands Children’s Hospital. The renovated unit features a larger waiting room, 16 infusion chairs each with a TV and gaming station, a compromised waiting area, nourishment area, more spaces for nurses, and so much more. Patients at each chair will have more room with more privacy.
To view more pictures of the infusion center, click here.
Clinical Trial Highlight: Refractory Cancers
This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with refractory malignancies.
Questions about how to send a patient? Please contact the Clinical Trials Office at cancer-center@ufl.edu or 352.273.8675
This open-label, single arm study is investigating the use of niraparib (an oral PARP inhibitor) in patients with tumors known to have mutations in BAP1 and a variety of other DNA damage response pathway genes. The primary aim is to determine the objective response rate of patients with BAP1 and other DDR repair pathway deficiencies. Cohorts include the histologies above (regardless of mutation) as well as any tumor histology with a confirmed DDR repair pathway mutation.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672
This is an investigator-initiated clinical trial that is based on the discovery of the importance of the Metnase complex in repairing chemotherapy-related DNA damage in leukemia. Ciprofloxacin has been identified as a metnase inhibitor that chemosensitizes leukemic myeloblasts to etoposide chemotherapy. The primary aims are to determine the maximum tolerated dose of ciprofloxacin that can be given in combination with a fixed dose of etoposide and determine the efficacy of the combination treatment in adults with resistant AML.
Principal Investigator: Randy Brown, M.D., cell: 859.221.6828
Adjuvant Pembrolizumab in Patients with Triple-Negative Breast Cancer
This phase III RCT assigns triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy to one year of adjuvant Pembrolizumab versus standard of care. Adjuvant Capecitabine is allowed. Principal Investigator: Karen Daily, DO, cell: 352.222.1423